KPC Pharmaceuticals Records 46% Higher Net Attributable Profit in 2024

MT Newswires Live

02/10

China Resources Pharmaceutical Group's (HKG:3320) subsidiary KPC Pharmaceuticals (SHA:600422) recorded net profit attributable to the shareholders of 648.1 million yuan in 2024, 46% higher than 444.7 million yuan logged before retrospective adjustment in 2023, a Monday bourse filing said.

KPC Pharmaceuticals' basic earnings per share for the reporting year were 0.86 yuan compared with 0.59 yuan per share recorded for the previous year.

The total operating revenue of the said subsidiary for the year was noted at 8.40 billion yuan, 9.1% higher than 7.70 billion yuan from a year ago.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2510499856"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2510499856\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2510499856?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-10 20:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2510499856","market":"sg","top_or_hot":-1,"title":"KPC Pharmaceuticals Records 46% Higher Net Attributable Profit in 2024","media":"MT Newswires Live","content":"<html><body><p> China Resources Pharmaceutical Group's (HKG:3320) subsidiary KPC Pharmaceuticals (SHA:600422) recorded net profit attributable to the shareholders of 648.1 million yuan in 2024, 46% higher than 444.7 million yuan logged before retrospective adjustment in 2023, a Monday bourse filing said.</p><p>KPC Pharmaceuticals' basic earnings per share for the reporting year were 0.86 yuan compared with 0.59 yuan per share recorded for the previous year.</p><p>The total operating revenue of the said subsidiary for the year was noted at 8.40 billion yuan, 9.1% higher than 7.70 billion yuan from a year ago.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>KPC Pharmaceuticals Records 46% Higher Net Attributable Profit in 2024</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKPC Pharmaceuticals Records 46% Higher Net Attributable Profit in 2024\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-02-10 20:13</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> China Resources Pharmaceutical Group's (HKG:3320) subsidiary KPC Pharmaceuticals (SHA:600422) recorded net profit attributable to the shareholders of 648.1 million yuan in 2024, 46% higher than 444.7 million yuan logged before retrospective adjustment in 2023, a Monday bourse filing said.</p><p>KPC Pharmaceuticals' basic earnings per share for the reporting year were 0.86 yuan compared with 0.59 yuan per share recorded for the previous year.</p><p>The total operating revenue of the said subsidiary for the year was noted at 8.40 billion yuan, 9.1% higher than 7.70 billion yuan from a year ago.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0028","symbol_name":"國家隊","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2510499856","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2510499856","pubTimestamp":1739189609,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"China Resources Pharmaceutical Group's  subsidiary KPC Pharmaceuticals  recorded net profit attributable to the shareholders of 648.1 million yuan in 2024, 46% higher than 444.7 million yuan logged before retrospective adjustment in 2023, a Monday bourse filing said.KPC Pharmaceuticals' basic earnings per share for the reporting year were 0.86 yuan compared with 0.59 yuan per share recorded for the previous year.The total operating revenue of the said subsidiary for the year was noted at 8.40 billion yuan, 9.1% higher than 7.70 billion yuan from a year ago.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600422":"昆药集团","BK0028":"国家队","BK0239":"医药制造","03320":"华润医药","BK0188":"融资融券","BK1191":"制药","BK1570":"华润系","BK0060":"抗癌"},"translate_title":"KPC Pharmaceuticals 2024年归属净利润增长46%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600422":0.9,"03320":0.9},"content_text":"China Resources Pharmaceutical Group's (HKG:3320) subsidiary KPC Pharmaceuticals (SHA:600422) recorded net profit attributable to the shareholders of 648.1 million yuan in 2024, 46% higher than 444.7 million yuan logged before retrospective adjustment in 2023, a Monday bourse filing said.KPC Pharmaceuticals' basic earnings per share for the reporting year were 0.86 yuan compared with 0.59 yuan per share recorded for the previous year.The total operating revenue of the said subsidiary for the year was noted at 8.40 billion yuan, 9.1% higher than 7.70 billion yuan from a year ago.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}